Journal: Materials Today Bio

Article Title: Feasibility of combining JAK1 gene editing via CRISPR-CasRx with EGCG–lactoferrin nanoparticle therapy in a microneedle-based platform for atopic dermatitis

doi: 10.1016/j.mtbio.2026.102884

Figure Lengend Snippet: Schematic illustration of microneedle delivery of JAK1-editing plasmids (CasRx) and EGCG-lactoferrin nanoparticles for the treatment of atopic dermatitis.

Article Snippet: Antibodies for JAK1, STAT3, p-STAT3, Nrf2, and HO-1 were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).

Techniques:

Journal: Materials Today Bio

Article Title: Feasibility of combining JAK1 gene editing via CRISPR-CasRx with EGCG–lactoferrin nanoparticle therapy in a microneedle-based platform for atopic dermatitis

doi: 10.1016/j.mtbio.2026.102884

Figure Lengend Snippet: Characterization and gene editing efficiency of PBAE-Plasmid NPs. ( a ) and ( b ) RNA silencing effects of different sgRNAs targeting JAK1 in NIH-3T3 and DC 2.4 cells. ( c ) Size and zeta potential of the PBAE-plasmid complex at various mass ratios. ( d ) Agarose gel electrophoresis of the PBAE/plasmid complex at different mass ratios. ( e ) Size distribution analyzed by dynamic light scattering (DLS) and transmission electron microscopy (TEM) images of PBAE-plasmid NPs at a mass ratio of 20:1. ( f ) and ( g ) Effects of the PBAE-plasmid complex at various mass ratios on NIH-3T3 and DC 2.4 cell viability. ( h ) Green fluorescence in NIH-3T3 cells transfected with PBAE-plasmid NPs. ( i ) JAK1 mRNA expression in NIH-3T3 cells transfected with PBAE-plasmid NPs. ( j ) JAK1 protein expression in mice transfected with PBAE-plasmid NPs. ( k ) Quantitative analysis of (j). Data are presented as mean ± SD (n = 3). Bars sharing the same letter are not significantly different, whereas those with different letters are statistically significant (p < 0.05).

Article Snippet: Antibodies for JAK1, STAT3, p-STAT3, Nrf2, and HO-1 were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).

Techniques: Plasmid Preparation, Zeta Potential Analyzer, Agarose Gel Electrophoresis, Transmission Assay, Electron Microscopy, Fluorescence, Transfection, Expressing

Journal: Materials Today Bio

Article Title: Feasibility of combining JAK1 gene editing via CRISPR-CasRx with EGCG–lactoferrin nanoparticle therapy in a microneedle-based platform for atopic dermatitis

doi: 10.1016/j.mtbio.2026.102884

Figure Lengend Snippet: Regulation of MN patches on the inflammation, JAK1 and Nrf2/HO-1 pathways in AD mice. ( a-c ) Levels of IL-1β, IL-4, and IL-13 in the dorsal skin. ( d, e ) Levels of TSLP and IgE in the serum. ( f ) Protein expression of JAK1 in the dorsal skin. ( g ) Quantitative analysis of JAK1 protein levels from (f). ( h ) 8-OHdG levels in the dorsal skin. ( i ) Fluorescent immunostaining of Nrf2, with the merged image showing DAPI staining (red: Nrf2, blue: DAPI). ( j ) Quantitative analysis of Nrf2 protein expression from (i). ( k ) Fluorescent immunostaining of HO-1, along with the merged image showing DAPI staining (red: HO-1, blue: DAPI). ( l ) Quantitative analysis of HO-1 protein expression from (k). Data are presented as mean ± SD (n = 6). Bars sharing the same letter are not significantly different, whereas those with different letters are statistically significant (p < 0.05).

Article Snippet: Antibodies for JAK1, STAT3, p-STAT3, Nrf2, and HO-1 were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).

Techniques: Expressing, Immunostaining, Staining